Phio is addressing some of the biggest challenges in immuno-oncology (I/O) by developing therapeutics that leverage our INTASYL™ self-delivering technology to target both tumor and immune cells. The I/O field has recently identified several promising next-generation targets, but conventional approaches such as antibodies and small molecules often fall short of becoming optimal treatments for patients. In contrast to conventional RNA inference (RNAi) platforms, our INTASYL™ enables efficient RNAi delivery into any cell of interest. INTASYL™ therefore brings the benefits of RNAi therapeutics into the I/O space to develop new and potent next-generation I/O therapeutics with favorable drug profiles for patients with cancer.
Our lead product, PH-762, targets the checkpoint protein PD-1, resulting in enhanced T-cell activation and tumor cytotoxicity.
PH-894 targets bromodomain-containing protein 4 (BRD4), improving T-cell function and persistence by differentiating T-cells into a more active state.
PH-804 targets the checkpoint protein TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains), thereby weaponizing immune cells to kill the cancer cells.